Opportunity Information: Apply for RFA RM 14 015
Apply for RFA RM 14 015
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Facile Methods and Technologies for Synthesis of Biomedically Relevant Carbohydrates (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.310 Trans NIH Research Support.
- This funding opportunity was created on Sep 30, 2014 and posted on Sep 30, 2014.
- Applicants must submit their applications by Dec 10, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $4,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- The number of recipients for this funding is limited to 6 candidate(s).
- Eligible applicants include: Public and State controlled institutions of higher education Special district governments Small businesses Private institutions of higher education County governments City or township governments Public housing authorities/Indian housing authorities For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled Additional Information on Eligibility for clarification) State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Native American tribal governments (Federally recognized).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Facile Methods and Technologies for Synthesis of Biomedically Relevant Carbohydrates (U01) (Funding Opportunity Number RFA-RM-14-015) was a National Institutes of Health (NIH) Common Fund cooperative agreement opportunity released under the Accelerating Translation of Glycoscience: Integration and Accessibility program. The core purpose of the program was to lower the practical barriers that keep many biomedical researchers from working with glycans (carbohydrates) by making glycoscience tools more accessible, affordable, and easier to use. The motivation behind the FOA is that carbohydrates and glycoconjugates play major roles in biology, health, and disease, but many investigators abandon glycan-related questions because the molecules are difficult to obtain, modify, and study with standard laboratory approaches. This opportunity specifically targeted the creation of new methods and technologies that would enable rapid, affordable synthesis, production, and/or functionalization of biomedically important glycans and glycoconjugates, with an emphasis on covering two broad biological spaces: mammalian glycomes and microbial glycans.
Scientifically, the FOA was focused on tool and technology development rather than purely descriptive biology. It sought approaches that could streamline the process of generating glycans and glyco-conjugates (for example, glycans attached to proteins, lipids, or other scaffolds), and that could make those products more readily available for downstream use across many fields, including immunology, infectious disease, cancer, neuroscience, and metabolic disease research. In practical terms, the FOA aimed to support innovations that reduce cost, increase speed and scalability, improve reproducibility, and expand the diversity of structures that can be made and functionalized, so that glycan standards, probes, reagents, and libraries can be produced more routinely and used widely by non-specialists. The emphasis on both mammalian and microbial glycans reflects the biomedical importance of host glycosylation (cell-cell communication, signaling, immune recognition) as well as pathogen-associated and microbiome-associated carbohydrate structures (virulence, immune evasion, vaccine antigen design, diagnostics).
From a funding and administrative standpoint, this was a discretionary federal grant opportunity using the cooperative agreement mechanism (U01), which typically means NIH staff anticipate substantial scientific/programmatic involvement during the project period compared with a standard investigator-initiated grant. The total estimated funding listed was about $4,000,000, with an award ceiling of $500,000, and the announcement anticipated around 6 awards. There was no cost-sharing or matching requirement. The activity category was health, and the CFDA listing was 93.310 (Trans-NIH Research Support), underscoring that this was a trans-NIH Common Fund effort intended to serve a broad biomedical community rather than a single disease institute mission.
Eligibility was broad and included many categories of U.S.-based organizations, such as public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), small businesses, other for-profit organizations (non-small businesses), state and local governments, tribal governments and tribal organizations, independent school districts, and certain special district and housing authorities. The eligibility language also explicitly included a range of mission-serving institutions (for example, HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, and AANAPISIs), as well as faith-based and community-based organizations and eligible federal agencies. Foreign organizations and foreign institutions were not eligible to apply as primary applicants, and non-U.S. components of U.S. organizations were not eligible, but foreign components (as defined by NIH policy) were allowed, which generally permits specific foreign collaboration elements when justified.
The FOA was posted on September 30, 2014, and closed on December 10, 2014, with an archive date of January 10, 2015, meaning it is no longer an active solicitation. For applicants at the time, the key competitive theme would have been a credible, well-justified plan to deliver enabling synthesis/production/functionalization capabilities that are broadly useful, lower the barrier to entry for glycoscience, and materially expand what the biomedical community can do with glycans and glycoconjugates in both mammalian and microbial contexts. The full announcement was hosted on the NIH grants site, and NIH’s Office of Extramural Research (OER) webmaster contacts were provided for access or linking issues.
FAQs: Facile Methods and Technologies for Synthesis of Biomedically Relevant Carbohydrates (U01) - RFA-RM-14-015
What is the name of this funding opportunity?
The opportunity was titled Facile Methods and Technologies for Synthesis of Biomedically Relevant Carbohydrates (U01).
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number was RFA-RM-14-015.
Which federal agency issued this FOA?
This was an opportunity from the National Institutes of Health (NIH), offered as part of the NIH Common Fund.
What NIH program did this opportunity fall under?
It was released under the NIH Common Fund program Accelerating Translation of Glycoscience: Integration and Accessibility.
What was the core purpose of the program behind this FOA?
The core purpose was to lower practical barriers that prevent many biomedical researchers from working with glycans (carbohydrates) by making glycoscience tools more accessible, affordable, and easier to use.
Why did NIH consider this area important?
The FOA was motivated by the fact that carbohydrates and glycoconjugates play major roles in biology, health, and disease, but many investigators avoid glycan-related research because these molecules can be difficult to obtain, modify, and study using standard lab approaches.
What types of projects were targeted?
The FOA specifically targeted creation of new methods and technologies enabling rapid, affordable synthesis, production, and/or functionalization of biomedically important glycans and glycoconjugates.
Was this FOA focused on basic biology discoveries or tool development?
It was focused on tool and technology development rather than purely descriptive biology.
What are "glycoconjugates" in the context of this FOA?
In this FOA, glycoconjugates refer to glycans attached to other scaffolds, such as proteins, lipids, or other molecular structures.
What kinds of improvements was NIH hoping to see from proposed technologies?
The FOA emphasized innovations that could reduce cost, increase speed and scalability, improve reproducibility, and expand the diversity of glycan and glycoconjugate structures that can be made and functionalized.
What downstream uses did NIH anticipate for the resulting glycan tools and products?
The FOA described broad downstream use across many fields, including immunology, infectious disease, cancer, neuroscience, and metabolic disease research.
What specific biological spaces were emphasized?
The opportunity emphasized coverage of two broad biological spaces: mammalian glycomes and microbial glycans.
Why did the FOA emphasize both mammalian and microbial glycans?
The FOA highlighted biomedical importance on both sides: host glycosylation (for example, cell-cell communication, signaling, immune recognition) and pathogen-associated/microbiome-associated carbohydrate structures (for example, virulence, immune evasion, vaccine antigen design, diagnostics).
What award mechanism was used?
This opportunity used the cooperative agreement mechanism: U01.
What does a U01 cooperative agreement generally imply?
As described in the opportunity summary, a U01 typically means NIH staff anticipate substantial scientific and/or programmatic involvement during the project period compared with a standard investigator-initiated grant.
What was the estimated total funding available?
The total estimated funding listed was about $4,000,000.
What was the award ceiling mentioned in the FOA summary?
The listed award ceiling was $500,000.
How many awards were anticipated?
The announcement anticipated around 6 awards.
Was cost sharing or matching required?
No. The summary indicated there was no cost-sharing or matching requirement.
What was the activity category for this opportunity?
The activity category was health.
What was the CFDA number associated with this FOA?
The CFDA listing was 93.310 (Trans-NIH Research Support).
What does the CFDA listing suggest about the program scope?
The CFDA listing underscored that this was a trans-NIH Common Fund effort intended to serve a broad biomedical community rather than a single disease institute mission.
Who was eligible to apply?
Eligibility was described as broad and included many categories of U.S.-based organizations, such as public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), small businesses, other for-profit organizations (non-small businesses), state and local governments, tribal governments and tribal organizations, independent school districts, and certain special district and housing authorities.
Were mission-serving institutions explicitly included?
Yes. The eligibility language explicitly included mission-serving institutions such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, and AANAPISIs, along with faith-based and community-based organizations.
Were federal agencies eligible to apply?
Yes. The eligibility language included eligible federal agencies.
Could foreign organizations apply as the primary applicant?
No. Foreign organizations and foreign institutions were not eligible to apply as primary applicants.
Could non-U.S. components of U.S. organizations apply?
No. Non-U.S. components of U.S. organizations were not eligible, as stated in the opportunity summary.
Were foreign components allowed at all?
Yes. The summary stated that foreign components (as defined by NIH policy) were allowed, generally permitting specific foreign collaboration elements when justified.
When was the FOA posted?
The FOA was posted on September 30, 2014.
When did the FOA close?
The FOA closed on December 10, 2014.
When was the FOA archived?
The archive date was January 10, 2015.
Is this FOA currently active?
No. Based on the posted, close, and archive dates provided, it is no longer an active solicitation.
What was the key competitive theme for applicants at the time?
The summary indicates applicants would have been expected to present a credible, well-justified plan to deliver enabling synthesis/production/functionalization capabilities that are broadly useful, lower the barrier to entry for glycoscience, and materially expand what the biomedical community can do with glycans and glycoconjugates in both mammalian and microbial contexts.
Where was the full announcement hosted?
The full announcement was hosted on the NIH grants site.
Who was listed for help with access or linking issues?
The opportunity indicated that NIH Office of Extramural Research (OER) webmaster contacts were provided for access or linking issues.
Browse more opportunities from the same category: Health
Next opportunity: Novel and Innovative Tools to Facilitate Identification, Tracking, Manipulation, and Analysis of Glycans and their Functions (R21)
Previous opportunity: National Digital Newspaper Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA RM 14 015
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA RM 14 015) also looked into and applied for these:
| Funding Opportunity |
|---|
| Novel and Innovative Tools to Facilitate Identification, Tracking, Manipulation, and Analysis of Glycans and their Functions (R21) Apply for RFA RM 14 014 Funding Number: RFA RM 14 014 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Novel and Innovative Tools to Facilitate Identification, Tracking, Manipulation, and Analysis of Glycans and their Functions (U01) Apply for RFA RM 14 013 Funding Number: RFA RM 14 013 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Data Integration and Analysis Tools Accessible Resources for Integration and Analysis of Carbohydrate and Glycoconjugate Structural, Analytical, and Interaction Data in the Context of Comparable Gene, Protein, and Lipid Data (R34) Apply for RFA RM 14 012 Funding Number: RFA RM 14 012 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Strengthen Capacity of the Ministry of Community Development, Mother and Child Health to Support National Coordination of HIV Prevention, Care and Treatment and Related Maternal, Neonatal and Child Health Serv at District FacilityCommunity Level (PEP Apply for CDC RFA GH15 1599 Funding Number: CDC RFA GH15 1599 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,975,000 |
| Strengthening the Healthcare System of Vietnam through Capacity Building, Policy Development and Quality Improvement of Laboratory and Clinical Services under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 1596 Funding Number: CDC RFA GH15 1596 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| Strengthening Human Resources for Health Capacity in the Republic of Rwanda under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 1568 Funding Number: CDC RFA GH15 1568 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $14,000,000 |
| Provision of Comprehensive HIV/AIDS, STI and TB Services Including Prevention, Care, Support and Treatment to Prisoners and Staff of the Prisons Service in the Republic of Uganda under the Presidents Emergency Plan for AIDS Relief Apply for CDC RFA GH15 1590 Funding Number: CDC RFA GH15 1590 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,200,000 |
| Support the Mandate of the Ministry of Health and Social Welfare in the United Republic of Tanzania to Centrally Coordinate National Blood Transfusion Services in order to Ensure an Adequate and Safe Blood Supply under PEPFAR Apply for CDC RFA GH15 1588 Funding Number: CDC RFA GH15 1588 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $5,000,000 |
| Implementing Technical and Science Support Services (TSSS) in the Republic of Rwanda under PEPFAR Apply for CDC RFA GH15 1570 Funding Number: CDC RFA GH15 1570 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $12,078,648 |
| Pre Symptomatic Profiles of Chronic Lung Disease(s) from Retrospective Cohorts (R21) Apply for RFA HL 15 025 Funding Number: RFA HL 15 025 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| The Midlife in the United States Study (U19) Apply for PAR 14 356 Funding Number: PAR 14 356 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Strengthening the Capacity of the Republican Blood Center to Scale Up Blood Safety Program in the Kyrgyzstan Republic under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CC RFA GH15 1512 Funding Number: CC RFA GH15 1512 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $100,000 |
| Strengthening the Capacity of the Republican Blood Center to Scale Up Blood Safety Program in Tajikistan (TJ) under the President Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 1513 Funding Number: CDC RFA GH15 1513 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $100,000 |
| Strengthening HIV Clinical Services in the Republic of Rwanda under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 1567 Funding Number: CDC RFA GH15 1567 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $30,000,000 |
| Building Sustainable Capacity of the Ministry of Home Affairs to Address HIV and TB Prevention, Care and Treatment in Zambian Prisons and Respond to Child Sexual Abuse and Sexual Gender Based Violence in the Republic of Zambia under the Presidents Em Apply for CDC RFA GH15 1601 Funding Number: CDC RFA GH15 1601 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,500,000 |
| Definition of Resilience and Pre Symptomatic Disease in Lung Health and Disease (R01) Apply for RFA HL 15 024 Funding Number: RFA HL 15 024 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Technical Assistance to Support the Implementation and Evaluation of HIV/AIDS Prevention, Care, Treatment, and Support Activities for Mothers, Children, and Families under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 1531 Funding Number: CDC RFA GH15 1531 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $6,000,000 |
| Strengthening Blood Transfusion Services in the Republic of Mozambique under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 1559 Funding Number: CDC RFA GH15 1559 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Regional Consortia for High Resolution Cryoelectron Microscopy (U24) Apply for RFA GM 16 001 Funding Number: RFA GM 16 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Ensuring Reliable and Equitable Access to PMTCT Services for Key Populations in the Republic of Mali under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 1605 Funding Number: CDC RFA GH15 1605 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $250,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA RM 14 015", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.